您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2021, Vol. 59 ›› Issue (9): 117-123.doi: 10.6040/j.issn.1671-7554.0.2021.0956

• 专家综述 • 上一篇    下一篇

卵巢癌耐药机制与靶向治疗策略的研究进展

哈春芳1,2,李茹月3   

  1. 1.宁夏医科大学总医院妇科, 宁夏 银川 750004;2.生育力保持教育部重点实验室, 宁夏 银川 750004;3.宁夏医科大学, 宁夏 银川 750004
  • 发布日期:2021-10-15
  • 通讯作者: 哈春芳. E-mail:hachunfang@163.com
  • 基金资助:
    宁夏重点研发项目(2019BFG02002)

Research progress of drug resistance in ovarian cancer and targeted therapy strategy

HA Chunfang1,2, LI Ruyue3   

  1. 1. Gynecology Department, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China;
    2. Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Yinchuan 750004, Ningxia, China;
    3. Ningxia Medical University, Yinchuan 750004, Ningxia, China
  • Published:2021-10-15

RichHTML

89

PDF (PC)

1832

摘要： 手术结合化疗是卵巢上皮性癌的主要治疗手段,其中以R0为目标的卵巢癌肿瘤细胞减灭术结合个体化的化疗方案的应用,使得部分患者5年生存率有了很大的提升。但是晚期患者的耐药与复发仍然是困扰广大临床医师与科研工作者的难题,而化疗耐药因其病因不清、机制复杂,是临床亟待解决的难题和热点。近年来围绕此问题开展的基础与临床相结合的卵巢癌耐药的机制研究主要包括药物转运、药物代谢、细胞凋亡、DNA损伤修复、表观遗传学改变等,细胞自噬、肿瘤代谢、肿瘤微环境及肿瘤干细胞等在卵巢癌耐药方面也发挥了重要作用,针对耐药机制的靶向药物治疗为提高化疗敏感性、改善患者预后提供了新的思路。

关键词: 卵巢癌, 耐药, 机制, 靶向治疗

Abstract: Cytoreductive surgery combined with chemotherapy is the major treatment of Epithelial ovarian cancer(EOC). The application of no residual disease(R0)targeted ovarian cancer debulking with individualized chemotherapy has greatly improved the five-year survival rates. However, the drug resistance and recurrence of advanced patients are still a difficult problem for clinicians and researchers in this field. Chemotherapy resistance is a hot and difficult spot to be solved urgently due to unclear etiology and complex mechanism. In recent years, the basic and clinical researches on the mechanism of drug resistance in ovarian cancer mainly include drug transport, drug metabolism, apoptosis, DNA damage repair and epigenetic changes. And some studies have shown that autophagy, altered metabolism, tumor microenvironment and tumor stem cells also have played an important role in drug resistance in ovarian cancer. The strategy targeting these mechanisms has provided a new method to increase sensitivity to chemotherapy and improve the prognosis.

Key words: Ovarian cancer, Drug resistance, Mechanism, Targeted treatment

中图分类号: 

  • R737.31
[1] Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41: 3-14. doi: 10.1016/j.bpobgyn.2016.08.006.
[2] Kalayda GV, Wagner CH, Jaehde U. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells [J]. J Inorg Biochem, 2012, 116: 1-10. doi: 10.1016/j.jinorgbio.2012.07.010.
[3] Jandial DA, Brady WE, Howell SB, et al. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: an NRG Oncology/Gynecologic Oncology Group study [J]. Gynecol Oncol, 2017, 145(2): 236-242.
[4] Lancaster CS, Sprowl JA, Walker AL, et al. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics [J]. Mol Cancer Ther, 2013, 12(8): 1537-1544.
[5] Svoboda M, Wlcek K, Taferner B, et al. Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport [J]. Biomed Pharmacother, 2011, 65(6): 417-426.
[6] Tong X, Zhao J, Zhang Y, et al. Expression levels of MRP1, GST-π, and GSK3β in ovarian cancer and the relationship with drug resistance and prognosis of patients [J]. Oncol Lett, 2019, 18(1): 22-28.
[7] Guo W, Dong W, Li M, et al. Mitochondria P-glycoprotein confers paclitaxel resistance on ovarian cancer cells [J]. Onco Targets Ther, 2019, 12: 3881-3891. doi: 10.2147/OTT.S193433.
[8] Gao B, Yang F, Chen W, et al. Multidrug resistance affects the prognosis of primary epithelial ovarian cancer [J]. Oncol Lett, 2019, 18(4): 4262-4269.
[9] Zhao MD, Li JQ, Chen FY, et al. Co-delivery of curcumin and paclitaxel by “core-shell” targeting amphiphilic copolymer to reverse resistance in the treatment of ovarian cancer [J]. Int J Nanomedicine, 2019, 14: 9453-9467. doi: 10.2147/IJN.S224579.
[10] Dobiasová S, Reho rová K, Ku cerová D, et al. Multidrug resistance modulation activity of silybin derivatives and their anti-inflammatory potential [J]. Antioxidants(Basel), 2020, 9(5): 455. doi: 10.3390/antiox9050455.
[11] Kawahara B, Ramadoss S, Chaudhuri G, et al. Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein [J]. J Inorg Biochem, 2019, 191: 29-39. doi: 10.1016/j.jinorgbio.2018.11.003.
[12] DeLoia JA, Zamboni WC, Jones JM, et al. Expression and activity of taxane-metabolizing enzymes in ovarian tumors [J]. Gynecol Oncol, 2008, 108(2): 355-360.
[13] van Eijk M, Boosman RJ, Schinkel AH, et al. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes [J]. Cancer Chemother Pharmacol, 2019, 84(3): 487-499.
[14] Yuan J, Lan H, Jiang X, et al. Bcl2 family: novel insight into individualized therapy for ovarian cancer(Review)[J]. Int J Mol Med, 2020, 46(4): 1255-1265.
[15] Zhang Y, Huang F, Luo Q, et al. Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer [J]. Onco Targets Ther, 2018, 11: 8751-8759. doi: 10.2147/OTT.S171053.
[16] Li RH, Yue C, Wei BB, et al. [In vivo study of siRNA silencing XIAP gene to reverse taxol-resistance in human ovarian cancer cells] [J]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2020, 51(3): 320-324.
[17] Usman RM, Razzaq F, Akbar A, et al. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance [J]. Asia Pac J Clin Oncol, 2021, 17(3): 193-208.
[18] Luan W, Pang Y, Li R, et al. Akt/mTOR-mediated autophagy confers resistance to BET inhibitor JQ1 in ovarian cancer [J]. Onco Targets The, 2019, 12: 8063-8074. doi: 10.2147/OTT.S220267.
[19] Tan WX, Xu TM, Zhou ZL, et al. TRP14 promotes resistance to cisplatin by inducing autophagy in ovarian cancer [J]. Oncol Rep, 2019, 42(4): 1343-1354.
[20] Wang J, Wu GS. Role of autophagy in cisplatin resistance in ovarian cancer cells [J]. J Biol Chem, 2014, 289(24): 17163-17173.
[21] Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: recent advances and future directions [J]. Cancer Discov, 2019, 9(9): 1167-1181.
[22] Dar S, Chhina J, Mert I, et al. Bioenergetic adaptations in chemoresistant ovarian cancer cells [J]. Sci Rep, 2017, 7(1): 8760. doi: 10.1038/s41598-017-09206-0.
[23] Han CY, Patten DA, Lee SG, et al. p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer [J]. Mol Carcinog, 2019, 58(11): 2161-2174.
[24] Bauerschlag DO, Maass N, Leonhardt P, et al. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer [J]. J Transl Med, 2015, 13: 146. doi: 10.1186/s12967-015-0511-3.
[25] Papaevangelou E, Almeida GS, Box C, et al. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model [J]. Int J Cancer, 2018, 143(4): 992-1002.
[26] Criscuolo D, Avolio R, Calice G, et al. Cholesterol homeostasis modulates platinum sensitivity in human ovarian cancer [J]. Cells, 2020, 9(4): 828. doi: 10.3390/cells9040828.
[27] Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics [J]. Cell Death Dis, 2013, 4(3): e532. doi: 10.1038/cddis.2013.60.
[28] Hudson CD, Savadelis A, Nagaraj AB, et al. Altered glutamine metabolism in platinum resistant ovarian cancer [J]. Oncotarget, 2016, 7(27): 41637-41649.
[29] Masamha CP, LaFontaine P. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy [J]. J Cell Biochem, 2018,119(7): 6136-6145.
[30] Schärer OD. Nucleotide excision repair in eukaryotes [J]. Cold Spring Harb Perspect Biol, 2013, 5(10): a012609. doi: 10.1101/cshperspect.a012609.
[31] Hassan M, Watari H, AbuAlmaaty A, et al. Apoptosis and molecular targeting therapy in cancer [J]. Biomed Res Int, 2014, 2014: 150845. doi: 10.1155/2014/150845.
[32] Guo J, Jin D, Wu Y, et al. Retraction notice to ‘The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells’ [EBioMedicine 35(2018)204-221] [J]. EBioMedicine, 2021, 63: 103168. doi: 10.1016/j.ebiom.2020.103168.
[33] Bogush TA, Popova AS, Dudko EA, et al. ERCC1 as a marker of ovarian cancer resistance to platinum drugs[J]. Antibiot Khimioter, 2015, 60(3-4): 42-50.
[34] Stefansson OA, Villanueva A, Vidal A, et al. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer [J]. Epigenetics, 2012, 7(11): 1225-1229.
[35] Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer [J]. Nature, 2015, 521(7553): 489-494.
[36] Wong-Brown MW, van der Westhuizen A, Bowden NA. Targeting DNA repair in ovarian cancer treatment resistance [J]. Clin Oncol(R Coll Radiol), 2020, 32(8): 518-526.
[37] Ali MW, Cacan E, Liu Y, et al. Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10(RGS10)gene in ovarian cancer cells [J]. PLoS One, 2013, 8(3): e60185. doi: 10.1371/journal.pone.0060185.
[38] Zeller C, Brown R. Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer [J]. Ther Adv Med Oncol, 2010, 2(5): 319-329.
[39] Moufarrij S, Dandapani M, Arthofer E, et al. Epigenetic therapy for ovarian cancer: promise and progress [J]. Clin Epigenetics, 2019, 11(1): 7. doi: 10.1186/s13148-018-0602-0.
[40] Mo L, Pospichalova V, Huang Z, et al. Ascites increases expression/function of multidrug resistance proteins in ovarian cancer cells [J]. PLoS One, 201, 10(7): e0131579. doi: 10.1371/journal.pone.0131579.
[41] Tang J, Zhu J, Ye Y, et al. Inhibition LC3B can increase chemosensitivity of ovarian cancer cells [J]. Cancer Cell Int, 2019, 19: 199. doi: 10.1186/s12935-019-0921-z.
[42] Nowak M, Klink M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer [J]. Cells, 2020, 9(5): 1299. doi: 10.3390/cells9051299.
[43] Zhang F, Cui JY, Gao HF, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis [J]. Future Oncol, 2020, 16(32): 2619-2633.
[44] Muñoz-Galván S, Carnero A. Targeting cancer stem cells to overcome therapy resistance in ovarian cancer [J]. Cells, 2020, 9(6): 1402. doi: 10.3390/cells9061402.
[45] Pieterse Z, Amaya-Padilla MA, Singomat T, et al. Ovarian cancer stem cells and their role in drug resistance [J]. Int J Biochem Cell Biol, 2019, 106: 117-126. doi: 10.1016/j.biocel.2018.11.012.
[46] Mihanfar A, Aghazadeh Attari J, Mohebbi I, et al. Ovarian cancer stem cell: a potential therapeutic target for overcoming multidrug resistance [J]. J Cell Physiol, 2019, 234(4): 3238-3253.
[47] Keyvani V, Farshchian M, Esmaeili SA, et al. Ovarian cancer stem cells and targeted therapy [J]. J Ovarian Res, 2019, 12(1): 120. doi: 10.1186/s13048-019-0588-z.
[1] 葛丽娟 金瑞峰 王纪文 许新升 李癊. 多药耐药基因1 C1236T多态性与癫痫患者对药物反应性的相关性[J]. 山东大学学报(医学版), 2209, 47(6): 99-102.
[2] 林明霞,刘桂斌,马燕花,连曌昱,任洋洋. ATP酶铜转运蛋白α介导的铜死亡途径及在肿瘤治疗中的价值[J]. 山东大学学报 (医学版), 2026, 64(4): 117-124.
[3] 黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.
[4] 王梦星,薛付忠,杨帆. 基于多模态交叉注意力机制融合的1型糖尿病血糖浓度预测方法[J]. 山东大学学报 (医学版), 2025, 63(8): 41-50.
[5] 张润泽,薛付忠,杨帆. 基于多模态解耦对比学习的癌症亚型聚类方法[J]. 山东大学学报 (医学版), 2025, 63(8): 51-60.
[6] 李晓琪,刘佩丽,成红,赵艳艳. 基于自注意力机制预测ICU脓毒症患者的死亡率[J]. 山东大学学报 (医学版), 2025, 63(8): 86-93.
[7] 罗淇,王霞,姜孟. 脑功能网络分析在失语症诊疗中的应用:病理机制分析、临床诊断与疗效评价[J]. 山东大学学报 (医学版), 2025, 63(8): 111-126.
[8] 王莹,李怀臣,龙飞,刘铱. 基于三种统计模型的长期空气污染物混合暴露与耐药性结核病发病风险关联[J]. 山东大学学报 (医学版), 2025, 63(7): 92-101.
[9] 梁炎春,严莹,麦华希,姚书忠. 地诺孕素在子宫内膜异位症相关性疼痛中的治疗作用:从基础到临床[J]. 山东大学学报 (医学版), 2025, 63(10): 27-33.
[10] 宋雅雯,郭联涛,孔德光,孙圣荣. VTCN1导致HR+乳腺癌预后不良及内分泌治疗耐药[J]. 山东大学学报 (医学版), 2025, 63(1): 43-59.
[11] 袁宗怀,潘广晔,迟曰梅,安传国,张永刚. 孟德尔随机化分析低级别浆液性卵巢癌与乳腺癌的因果关系[J]. 山东大学学报 (医学版), 2025, 63(1): 99-107.
[12] 王莉莎,王上增,史栋梁,张仲博,任博文,王云飞,郭中华,周晓宁. 乌头汤对膝骨关节炎大鼠模型的治疗作用[J]. 山东大学学报 (医学版), 2024, 62(5): 64-71.
[13] 刘超,刁婷婷,张红吉,刘红伟,杨永锐,李晓非. 飞行时间质谱在耐药结核病检测中的应用价值[J]. 山东大学学报 (医学版), 2024, 62(4): 61-67.
[14] 杨闯,张荣雨,宋彬,王程君,赵文,玄甜甜,李际盛. 阿美替尼一线治疗EGFR突变肺腺癌伴大疱性类天疱疮1例并文献复习[J]. 山东大学学报 (医学版), 2024, 62(12): 32-37.
[15] 王亚楠,梁传杰,贾梦琪,苑辉卿. 二硫键异构酶TMX1促进肺癌化疗耐药[J]. 山东大学学报 (医学版), 2023, 61(8): 31-39.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发